Back to Search Start Over

Activation of mGlu2/3 receptors in the striatum alleviates L-DOPA-induced dyskinesia and inhibits abnormal postsynaptic molecular expression.

Authors :
Tan, Yang
Cheng, Chi
Zheng, Cong
Zeng, Weiqi
Yang, Xiaoman
Xu, Yu
Zhang, Zhaoyuan
Ma, Zhuoran
Xu, Yan
Cao, Xuebing
Source :
Pharmacology, Biochemistry & Behavior. Oct2023, Vol. 231, pN.PAG-N.PAG. 1p.
Publication Year :
2023

Abstract

Group II metabotropic glutamate receptors (mGlu 2/3 receptors) have been regarded as promising candidates for the treatment of L-DOPA-induced dyskinesia (LID); however, confirmation is still lacking. As the hub of the basal ganglia circuit, the striatum plays a critical role in action control. Supersensitive responsiveness of glutamatergic corticostriatal input may be the key mechanism for the development of LID. In this study, we first examined the potency of LY354740 (12 mg/kg, i.p.) in modulating glutamate and dopamine release in lesioned striatum of stable LID rats. Then, we injected LY354740 (20nmoL or 40nmoL in 4 μL of sterile 0.9 % saline) directly into the lesioned striatum to verify its ability to reduce or attenuate L-DOPA-induced abnormal involuntary movements. In experiment conducted in established LID rats, after continuous injection for 4 days, we found that LY354740 significantly reduced the expression of dyskinesia. In another experiment conducted in parkinsonism rat models, we found that LY354740 attenuated the development of LID with an inverted-U dose–response curve. The role of LY354740 in modulating striatal expressions of LID-related molecular changes was also assessed after these behavioral experiments. We found that LY354740 significantly inhibited abnormal expressions of p-Fyn/p-NMDA/p-ERK1/2/p-HistoneH3/ΔFosB, which is in line with its ability to alleviate abnormal involuntary movements in both LID expression and induction phase. Our study indicates that activation of striatal mGlu 2/3 receptors can attenuate the development of dyskinesia in parkinsonism rats and provide some functional improvements in LID rats by inhibiting LID-related molecular changes. • Activation of striatal mGluR2/3 can reduce the expression of dyskinesia. • Activation of striatal mGluR2/3 can attenuate the development of dyskinesia. • mGluR2/3 agonist can inhibit LID-associated molecular alterations. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00913057
Volume :
231
Database :
Academic Search Index
Journal :
Pharmacology, Biochemistry & Behavior
Publication Type :
Academic Journal
Accession number :
172345587
Full Text :
https://doi.org/10.1016/j.pbb.2023.173637